Application of radix astragali seu hedysari glucoside in treatment of cerebral arterial thrombosis
Activating the PPARγ signaling pathway through astragaloside promotes M2 transformation of microglia, solving the problem of neuroinflammatory regulation in the treatment of acute ischemic stroke, significantly improving the neuroprotective effect after stroke, and providing ischemic stroke with ischemic stroke New treatment ideas and drug development directions.
Patent Information
- Application Number
- CN202411240182.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-19
AI Technical Summary
Existing treatment methods for acute ischemic stroke such as recombinant tissue-type plasminogen activators and intravascular mechanical thrombectomy have narrow therapeutic windows and side effects, and the neuroinflammatory response after ischemic stroke is difficult to effectively regulate, which affects the effect of Prognosis.
By using astragaloside to activate the PPARγ signaling pathway, it promotes the transformation of microglia into M2 type, thereby regulating the neuroinflammatory response and achieving repair and protection of brain tissue.
Astragaloside significantly improves neuroprotection after ischemic stroke, reduces inflammatory response and brain damage, provides new treatment strategies and drug development directions, and improves the safety and effectiveness of treatment.
Smart Images

Figure CN118976039A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to an application of huangshi glycoside in the treatment of ischemic stroke. Background Art
[0002] Approximately 69.6%-70.8% of strokes are ischemic strokes. Ischemic strokes are usually caused by a transient or permanent reduction in local cerebral blood flow. The current treatment strategies for acute ischemic stroke are blood flow restoration and neuroprotection. Recombinant tissue plasminogen activator (rt-PA) and endovascular mechanical thrombectomy are one of the most effective clinical treatments for acute ischemia, but the efficacy and safety of these therapeutic applications are limited due to their narrow therapeutic window and side effects. Therefore, it is very urgent to understand the pathophysiology of ischemic brain injury, find new therapeutic targets, and develop other strategies that can enhance neurovascular repair after cerebral ischemia / reperfusion injury.
[0003] After the onset of ischemic stroke, a strong and persistent neuroinflammatory response is rapidly triggered, releasing various inflammatory factors. Although the inflammatory response helps to remove necrotic tissue and maintain the stability of the internal environment, it can also aggravate brain damage, damage the blood-brain barrier, and hinder tissue repair. Neuroinflammation after ischemic stroke is an important factor affecting the prognosis of ischemic brain injury. Therefore, effectively regulating neuroinflammation after cerebral infarction is a possible breakthrough in the treatment of cerebral infarction.
[0004] Once an ischemic stroke occurs, it immediately triggers the body's innate immune response. The first immune cells to sense the occurrence of ischemic stroke are microglia, which are innate immune cells that have the ability to sense imbalances in the central nervous system. Studies have found that activated microglia have two different biological phenotypes: M1 and M2. M1 microglia can promote inflammatory response and aggravate tissue damage, and can produce inflammatory mediators such as interleukin-1β (IL-1β) and tumor necrosis factor (TNF-α), and can be detected by cell surface markers such as CD16, CD32, CD80, CD86 and inducible nitric oxide synthase (iNOS). M2 microglia can inhibit inflammatory response and promote tissue repair, and can produce interleukin-4 (IL-4), IL-10, IL-13, transforming growth factor β (TGF-β), and can be detected by cell surface markers such as arginase 1 (Arginase1, Arg1) and CD206. M1 and M2 microglia can transform into each other under certain conditions. By regulating the phenotype of microglia, it is expected to reduce nerve tissue damage and improve the symptoms of neurological deficits after stroke. Therefore, how to regulate the polarization direction of microglia is a key link in regulating neuroinflammation.
[0005] Recent studies have shown that peroxisome proliferator activated receptors (PPARs) are closely related to stroke. PPARs are free ligand-activated nuclear transcription factors in the nuclear receptor superfamily, including three subtypes: PPARα, PPARβ, and PPARγ. They mainly exert corresponding biological effects by regulating gene transcription and play an important protective role in a variety of central nervous system diseases, especially ischemic stroke. PPAR-γ is a nuclear transcription factor that is significantly associated with the regulation of microglial inflammatory phenotypes. It is an important transcription factor that regulates cellular inflammatory responses after ischemic stroke and participates in inflammatory regulation. It is believed to play a vital role in regulating the conversion of microglia to M2 type. Animal experiments have shown that the administration of PPARγ agonists can inhibit inflammatory responses, reduce oxidative stress, and thus play a protective role against brain damage caused by ischemia-reperfusion.
[0006] Astragaloside IV, a traditional Chinese medicine for invigorating qi, is a commonly used drug in traditional Chinese medicine for the treatment of ischemic cerebrovascular disease, and its history of use has exceeded thousands of years. Astragaloside IV, as a quality control marker component of Astragalus, is one of its main effective components, and has multiple pharmacological effects such as immune regulation, anti-inflammatory, anti-apoptosis, neuroprotection, and vascular remodeling. Astragaloside IV, used alone or in combination with other traditional Chinese medicine components and treatment methods, can improve the neurological deficits of experimental animals, reduce the volume of cerebral infarction, and reduce the permeability of the blood-brain barrier, and reduce brain edema and damage to neurons by harmful metabolites by inhibiting oxidative stress and inflammatory response, improving the energy metabolism of brain tissue after reperfusion, inhibiting the reduction and disappearance of Nissl bodies, and neuronal apoptosis. However, it is not completely clear whether astragaloside IV regulates microglial polarization after cerebral ischemia and its long-term neuroprotective effect on cerebral ischemia / reperfusion injury and its potential mechanism. Summary of the invention
[0007] In view of the above findings, the present invention uses a rat model of middle cerebral artery occlusion to observe the regulatory effect of astragaloside IV on the polarization of M2 microglia in ischemic stroke and its regulation of neuroinflammation through the PPARγ signaling pathway, in order to provide a reference basis and theoretical support for its application in clinical stroke patients, and to provide new ideas and directions for the clinical treatment of ischemic stroke with traditional Chinese medicine.
[0008] The object of the present invention is to provide a pharmaceutical composition for treating ischemic stroke, comprising huangshi glycoside A, wherein the huangshi glycoside A promotes the transformation of microglia to M2 type by activating PPARγ signaling pathway.
[0009] As a preferred embodiment of the present technical solution, a PPARγ agonist is also included, and the PPARγ agonist is an agent that activates the PPARγ signaling pathway.
[0010] In addition, the present invention proposes the use of a PPARγ agonist in the preparation of a drug for inhibiting ischemic stroke, which promotes the transformation of microglia to M2 type by activating the PPARγ signaling pathway.
[0011] In addition, the present invention also provides an application of huangshi glycoside in the preparation of a drug for activating the PPARγ signaling pathway.
[0012] Compared with the prior art, the present invention has the following advantages:
[0013] 1. The present invention clarifies that astragaloside IV has a neuroprotective effect on rats after ischemic stroke, proving that astragaloside IV has the value of further development in the prevention and treatment of ischemic stroke, and has the prospect of becoming an ideal drug for the prevention and treatment of ischemic stroke. Astragaloside IV has the potential to be further developed into a new drug for subsequent research and clinical application, providing a new direction.
[0014] 2. The present invention discovered the role of the PPARγ pathway in the treatment of ischemic stroke, providing a reference for the development of related drugs based on the PPARγ signaling pathway. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 It is a thinking map guiding the animal experiment technology in the present invention. DETAILED DESCRIPTION
[0016] The present invention is further described below with reference to specific examples.
[0017] 1. Experimental ideas
[0018] like Figure 1 As shown in the figure, the SD rat middle cerebral artery occlusion (MCAO) model constructed in the laboratory was divided into 3 groups: surgical control group, surgery + astragaloside group, surgery + astragaloside group + GW9662 (PPARγ inhibitor) group. After the model was successfully established, the degree of neurological deficit in the rats was evaluated on the 3rd, 7th and 14th days after the above treatment. The rats were killed 14 days later, and the volume of cerebral infarction in the rats was evaluated by triphenyltetrazolium chloride (TTC) staining. Immunofluorescence histochemistry was performed to detect Ibal + CD1 6+ Ibal + The number of CD206 cells was measured, the gray value of iNOS and Arg1 was detected by Western blot after the extraction of rat brain tissue protein, and the expression of IL-1β, TNF-α, IL-6, IL-10, and TGF-β was detected by qRT-PCR after the extraction of rat brain tissue RNA, so as to clarify the neuroprotective effect and mechanism of astragaloside IV on rats with cerebral ischemia.
[0019] 2. Experimental methods
[0020] 2.1 Construction of rat middle cerebral artery occlusion (MCAO) model
[0021] The rat middle cerebral artery occlusion (MCAO) model was established according to the method of Longa et al. Sixty 7-week-old male SD rats were fasted for 12 hours before surgery. After intraperitoneal injection of 10% chloral hydrate (350 mg / kg), the right common carotid artery, external carotid artery, and internal carotid artery were separated in turn. The trunk of the external carotid artery was ligated and freed. A small cut was made in the external carotid artery, and the suture was gently inserted into the internal carotid artery through the external carotid artery. When the nylon line was inserted 18-20 mm from the bifurcation of the common carotid artery and there was slight resistance, the suture was gently pulled out after 90 minutes of ischemia to restore blood perfusion. The external carotid artery was ligated and the skin was sutured. The rats were heated with a heating blanket and an incandescent lamp during the operation to maintain the rectal temperature at about 37°C. After surgery, they were placed in a constant temperature box until they woke up. After the rats woke up, behavioral evaluation was performed according to the Longa5 scoring scale, and rats with scores of 1-3 were included in subsequent experiments.
[0022] Longa5 neurological deficit scoring standard
[0023]
[0024] 2.2 Experimental groups and drug administration
[0025] Rats with middle cerebral artery occlusion constructed in the laboratory or purchased directly were randomly divided into 3 groups, with 20 rats in each group:
[0026] a. MCAO group: normal saline was injected intraperitoneally every day after surgery for 14 consecutive days;
[0027] b. MCAO+astragaloside IV group: Astragaloside IV (mass fraction 1%) was dissolved in isotonic sodium chloride solution containing 5% ethanol and intraperitoneally injected 1 hour after surgery at a dose of 40 mg / kg, once a day for 14 consecutive days;
[0028] c. MCAO+astragaloside IV+GW9662 (PPARγ antagonist) group: GW9662 1 mg / kg (dissolved in 2% DMSO) was injected into the lateral ventricle 30 minutes before surgery, and astragaloside IV 40 mg / kg was injected intraperitoneally 1 hour after surgery, once a day for 14 consecutive days.
[0029] 2.3 Evaluation of neurological deficits in rats
[0030] The rats were subjected to neurological deficit score (mNSS) on the 3rd, 7th and 14th days after surgery, including motor, sensory, reflex and balance tests. The mNSS score ranges from 0 to 18 points, with 0 being the normal score. The higher the score, the more severe the neurological deficit of the rat.
[0031] mNSS Rating Table
[0032]
[0033]
[0034] 2.4 TTC staining and measurement of cerebral infarct volume
[0035] The rats were killed after completing the mNSS score on the 14th day after surgery. Five rats were taken from each group and killed after anesthesia with 10% chloral hydrate. The olfactory bulb and cerebellum were removed, and the brain tissue was kept frozen at -20℃ for 20 minutes. It was cut into 6 slices along the coronal plane with a thickness of 2mm. The brain tissue slices were placed in 2% TTC staining solution and stained at 37℃ in the dark for 15-20 minutes. Analysis of staining results: Normal brain tissue is red, and infarcted brain tissue is white. Photos were taken. The cerebral infarction area was measured with Image-Pro Plus software, and the cerebral infarction volume was calculated and corrected according to the following formula: Infarction volume percentage (%) = [left hemisphere volume - (right hemisphere volume - infarction volume)] / left hemisphere volume × 100%.
[0036] 2.5 Fluorescent immunostaining detection of Ibal + CD16 + Ibal + CD206 + Number of cells
[0037] mNSS scoring was completed on the 14th day after surgery. Five rats from each group were selected and the rats were perfused with 4% paraformaldehyde (PFA) after deep isoflurane inhalation anesthesia. The brain was removed and coronal sections were made, and the sections were embedded in paraffin with a thickness of 4 μm. The sections were incubated with Iba-1, CD16, CD206, and NeuN antibodies at 4°C overnight and then labeled with fluorescently conjugated secondary antibodies. DAPI was used to stain the cell nuclei.
[0038] Degenerating neurons were detected by Fluore Jade C (FJC) staining. According to the instructions of the FJC staining kit, the slices were first immersed in 0.01% potassium permanganate solution, and then incubated with FJC solution at room temperature in the dark for 20 minutes. DAPI was used to stain the cell nucleus.
[0039] The images were captured by a fluorescence microscope to observe the local lesions in the ischemic cortex of the right brain. The images were analyzed and modified by Image J software, and the fluorescence intensity was used to represent the protein expression.
[0040] 2.6 Western blot detection of gray values of iNOS and Arg1
[0041] mNSS scoring was completed on the 14th day after surgery, and 5 rats were selected from each group. After anesthesia, the rats were quickly decapitated to remove the reperfused brain tissue on the ischemic side and stored in a refrigerator in liquid nitrogen at -80°C. The cerebral cortex around the infarction was dissected, quickly ground, and the supernatant was aspirated with protein lysis buffer. The total protein concentration of the supernatant was quantitatively detected by the BCA method. Nuclear and cytoplasmic protein extraction kits were used to extract nuclear and cytoplasmic proteins, respectively, and proteins of different molecular weights were separated by polyacrylamide gel electrophoresis. The proteins in the gel were then electrotransferred to a PVDF membrane. After the transfer, the PVDF membrane was blocked in 5% skim milk.
[0042] Subsequently, the membrane was incubated with primary antibodies (iNOS, Arg1, H3, and β-tubulin) at 4°C overnight. HRP-labeled secondary antibodies were then used to label the primary antibodies bound to the membrane. A color developer solution was used for color development. Grayscale value quantitative analysis was performed using Image J software.
[0043] 2.7 Detection of mRNA expression of IL-1β, TNF-α, IL-6, IL-10, and TGF-β by quantitative RT-PCR
[0044] After the scoring was completed, 5 rats in each group were anesthetized with chloral hydrate. After successful anesthesia, the abdominal skin of the rats was cut open along the costal arch, the common abdominal artery and the inferior vena cava were separated after the liver was fully exposed, and the two blood vessels were clamped with a vascular clamp. Then the diaphragm was cut open with a scissor, the sternum was cut open along the midline to expose the heart, the right atrial appendage was cut open to see blood flowing out, and the left ventricle was punctured and perfused with a sufficient amount of PBS solution until the bilateral eyeballs and tongue faded to white. After the perfusion was completed, the rats were decapitated in an ice bath, the skull skin was cut open, and the skull and dura mater were opened to remove the whole brain tissue.
[0045] The rat ischemic brain tissue was collected and total RNA was extracted with phenol and chloroform. According to the instructions of the TAKARA reverse transcription kit, the RNA samples were reverse transcribed into complementary DNA at 37°C for 15 min and 95°C for 5 s. The complementary DNA was then amplified using the TAKAR qPCR kit, and the Ct value was recorded according to the amplification curve. The relative expression of different mRNAs was calculated based on the Ct value.
[0046] 2.8 Statistical methods
[0047] SPSS20.0 was used for statistical analysis. The values were expressed as (x±s). The behavioral scores were analyzed using the non-parametric Kruskal-Wallis H test. The rest were analyzed using one-way analysis of variance. The Student-Newman-Keuls method was used for pairwise comparisons between groups. P < 0.05 was considered statistically significant.
[0048] 3. Results
[0049] (1) Astragaloside IV plays a brain repair role and restores the function of cerebral ischemia-reperfusion injury by promoting microglial M2 polarization.
[0050] (2) Astragaloside IV promotes the transformation of microglia to M2 type by activating the PPARγ signaling pathway.
[0051] (3) Astragaloside IV improves the prognosis of ischemic stroke by regulating the PPARγ pathway.
[0052] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention, rather than to limit the protection scope of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. A pharmaceutical composition for treating ischemic stroke, characterized in that: The invention comprises huangshi glycoside IV, which promotes the transformation of microglia to M2 type by activating PPARγ signaling pathway.
2. The pharmaceutical composition according to claim 1, characterized in that Also included are PPARγ agonists, which are agents that activate the PPARγ signaling pathway.
3. Use of a PPARγ agonist in the preparation of a drug for inhibiting ischemic stroke, characterized in that: It promotes the transformation of microglia to M2 type by activating the PPARγ signaling pathway.
4. Application of huangshi glycoside in the preparation of drugs that activate PPARγ signaling pathway.
Citation Information
Cited By
Medicine for preventing and treating cerebral arterial thrombosis
CN119792487A
